Sequencing Targeted Therapies and Approaches for Genomic Versus Non-Genomic Cases

This segment explores targeted therapy sequencing for hormone receptor-positive metastatic breast cancer. Dr. Traina and the panel discusses the management of patients with detected actionable mutations, outlining the use of CDK4/6 inhibitors, endocrine therapies, and pathway-targeted agents such as PI3K and AKT inhibitors. For patients without actionable genomic alterations, evidence from the Maintain and Monarch studies is discussed to support CDK4/6 inhibitor rechallenge and combination strategies. Panelists delve into the nuances of using agents like everolimus and how mutation profile impacts the choice between aromatase inhibitors or fulvestrant as backbones in later-line settings. The session underscores the ever-expanding landscape of post-CDK4/6 options and the integration of new evidence in clinical practice.